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Abstract
Background: Ukraine was the epicentre of the HIV epidemic in Eastern Europe, which has the
most rapidly accelerating HIV epidemic world-wide today; national HIV prevalence is currently
estimated at 1.6%. Our objective was to evaluate the uptake and effectiveness of interventions for
prevention of mother-to-child transmission (PMTCT) over an eight year period within operational
settings in Ukraine, within the context of an ongoing birth cohort study.
Methods: The European Collaborative Study (ECS) is an ongoing birth cohort study in which HIV-
infected pregnant women identified before or during pregnancy or at delivery were enrolled and
their infants prospectively followed. Three centres in Ukraine started enrolling in 2000, with a
further three joining in September 2006.
Results: Of the 3356 women enrolled, 21% (689) reported current or past injecting drug use
(IDU). Most women were diagnosed antenatally and of those, the proportion diagnosed in the first/
second trimester increased from 47% in 2000/01 (83/178) to 73% (776/1060) in 2006/07 (p <
0.001); intrapartum diagnosis was associated with IDU (Adjusted odds ratio 4.38; 95%CI 3.19–
6.02). The percentage of women not receiving any antiretroviral prophylaxis declined from 18%
(36/205) in 2001 to 7% in 2007 (61/843) (p < 0.001). Use of sdNVP alone substantially declined
after 2003, with a concomitant increase in zidovudine prophylaxis. Median antenatal zidovudine
prophylaxis duration increased from 24 to 72 days between 2000 and 2007. Elective caesarean
section (CS) rates were relatively stable over time and 34% overall. Mother-to-child transmission
(MTCT) rates decreased from 15.2% in 2001 (95%CI 10.2–21.4) to 7.0% in 2006 (95%CI 2.6–14.6).
In adjusted analysis, MTCT risk was reduced by 43% with elective CS versus vaginal delivery and
by 75% with zidovudine versus no prophylaxis.
Conclusion:  There have been substantial improvements in use of PMTCT interventions in
Ukraine, including earlier diagnosis of HIV-infected pregnant women and increasing coverage with
antiretroviral prophylaxis and the initial MTCT rate has more than halved. Future research should
focus on hard-to-reach populations such as IDU and on missed opportunities for further reducing
the MTCT rate.
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Background
Ukraine has the most severe HIV epidemic in the whole of
Europe and the Commonwealth of Independent States
with an estimated 440,000 people living with HIV/AIDS
and an adult HIV prevalence rate of 1.6% [1-3]. Ukraine
was the epicentre of the HIV epidemic in the region [4]
and although injecting drug use (IDU) was the main
driver of the epidemic, heterosexual transmission has sub-
sequently increased substantially [5-8]. The increased het-
erosexual transmission of HIV is closely linked to risky
sexual behaviour among and with injecting drug users [3].
Women account for nearly half of the infected popula-
tion, with an estimated 190,000 women living with HIV/
AIDS, the vast majority in their child-bearing years [8].
Most HIV infections in children occur through mother-to-
child transmission (MTCT), which can take place in utero,
intrapartum and through breastfeeding [9]. The WHO/
UNAIDS Strategic response to prevention of HIV infection
in infants involves four "pillars"-primary prevention of
infection in women, prevention of unintended pregnan-
cies in HIV-infected women, prevention of transmission
from HIV-infected women to their infants and provision
of treatment, care and support to HIV-infected women
and their families [10,11]. Interventions effective for the
prevention of MTCT (PMTCT) include antiretroviral
(ARV) prophylaxis, elective caesarean section (CS) and
avoidance of breastfeeding [12]. In resource-rich settings,
where antenatal highly active antiretroviral therapy
(HAART) is extensively used, MTCT rates have declined
from around 16–25% in non-breastfeeding women to less
than 1–2% [13-15]. In resource-limited settings, various
abbreviated ARV prophylactic regimens have been shown
to be effective PMTCT interventions, with single dose nev-
irapine (sdNVP) the most commonly used to date,
although concerns exist regarding emergence of resistance
following sdNVP exposure [12,16].
Ukraine adopted its first Programme for Preventing HIV
in Newborns in 2001 [17], involving an opt-out universal
antenatal HIV testing policy, sdNVP for infected mothers
and their infants and provision of free infant formula. Fol-
lowing a review in 2003, the programme was updated
with zidovudine (ZDV) starting from at least 28 weeks
gestation and one week of neonatal ZDV prophylaxis to
replace sdNVP; for women identified as HIV-infected after
28 weeks gestation, the addition of sdNVP to ZDV for
mother and infant was recommended, while infants of
mothers identified intrapartum should also receive
extended (four weeks) ZDV prophylaxis [18].
Our aim was to evaluate the uptake and effectiveness of
PMTCT interventions over an eight year period in
Ukraine, within a multicentre cohort study of HIV-
infected pregnant women and their infants, the European
Collaborative Study (ECS).
Methods
Study setting and subjects
The ECS is an ongoing birth cohort study, in which HIV-1
infected pregnant women are enrolled and their infants
prospectively followed according to a standard protocol.
The ECS was established in 1985 in Western Europe to
estimate the rate of and risk factors for MTCT [19]. Centres
from Ukraine joined in 2000: sites in Odessa, Mykolaiv
and Simferopol started enrolling at the start of 2000 and
those in Kiev, Donetsk and Mariupol in September 2006
[15].
In Ukraine, antenatal care services are free of charge
(including HIV testing), and antenatal care coverage
increased from 90% in 1999 to 99% in 2007, with almost
all deliveries taking place in health facilities. For 2003–
2007, the infant mortality estimate was 14 per 1,000 live
births [20]. Pregnant women in Ukraine are screened for
HIV infection at pregnancy registration and for those test-
ing negative there is repeat testing at around 30 weeks ges-
tation. HIV testing is free and included within the
standard antenatal care package. A national policy for
offering rapid testing during labour for women who have
presented with unknown HIV status, was introduced in
2003, those who were tested positive received sdNVP
prophylaxis. All pregnant women identified as HIV-
infected before or during pregnancy, or through intrapar-
tum testing, were invited to participate in the ECS, with
informed consent. Data are collected anonymously on
standard questionnaires, using study serial numbers,
without personal identifiers (linked anonymous data).
Information collected includes maternal socio-demo-
graphic and clinical information, delivery and infant char-
acteristics. Flow cytometry became available in Odessa
and Simferopol in 2004; Donetsk and Kiev had this capac-
ity from their first enrolments in autumn 2006. HIV-
infected infants were diagnosed based on persistence of
HIV antibody beyond age 18 months up until the start of
2006; subsequently, early diagnosis of HIV-exposed
infants with PCR testing was introduced nationwide, with
facilities in three inter-regional laboratories. However,
coverage (both nationally and within ECS sites) remains
patchy due to slow uptake of the rapid testing service in
some AIDS centres and a period when no rapid testing
was available at one of the inter-regional laboratories due
to technical problems [21]; 40% (276/698) of infants
born in 2006 and enrolled in the ECS had PCR test results
available.
Definitions
Infants with persistence of antibody beyond 18 months of
age and/or a positive virological marker of infection
regardless of age were included as HIV-infected. If a child
was HIV antibody-negative and no virus had been
detected, (s)he was classified as uninfected, regardless of
age. Elective CS deliveries were classified as occurringBMC Infectious Diseases 2009, 9:40 http://www.biomedcentral.com/1471-2334/9/40
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before rupture of membranes and onset of labour. Prema-
ture delivery was defined as occurring before 37 com-
pleted weeks of gestation. Injecting drug use (IDU) history
(current or past) was assigned according to self-report,
clinical report or neonatal drug withdrawal symptoms.
Maternal moderate/severe HIV symptoms were defined as
those in WHO Clinical stage 3 or 4. Multiple births (32
twin pairs) were treated as separate mother-child pairs.
Data analysis
Univariable comparisons were assessed with the χ2 test for
categorical variables. Logistic regression was used to
obtain unadjusted odd ratios (OR) and adjusted odds
ratios (AOR) and 95% confidence intervals (CI) in analy-
ses identifying factors associated with timing of maternal
HIV diagnosis and to investigate risk factors for non-
receipt of ARV prophylaxis and for MTCT. The analyses for
factors associated with pre-pregnancy diagnosis were lim-
ited to 2871 women with complete data available on:
mode of HIV acquisition, time period, maternal age and
HIV symptoms. The regression analyses of intrapartum
maternal diagnosis included the above variables and were
limited to 2336 women with unknown HIV status at con-
ception. The analysis investigating non-receipt of ARV
prophylaxis included time of maternal HIV diagnosis,
maternal age, mode of acquisition, gestational age and
time period, with 3224 women with complete data
included. The analysis of MTCT risk included 1635
mother-child pairs with known infant infection status and
no missing information on the explanatory variables (pre-
maturity, mode of delivery, ARV prophylaxis, IDU history
and breastfeeding). Statistical analyses were performed
with SAS (v8.02, SAS Institute, Cary, North Carolina,
USA).
Ethics approval
The ECS has been approved by the Great Ormond Street
Hospital for Children NHS Trust/Institute of Child Health
Ethics Committee.
Results
HIV-infected pregnant women
By January 2008, 3356 mother-child pairs had been
enrolled. Most women were young, nulliparous, married
or cohabiting and reported no specific HIV acquisition
risk factors (Table 1). Fifteen (0.5%) women were born
outside Ukraine, mostly elsewhere in the Commonwealth
of Independent States. Of the 689 women with an IDU
history, 357 (52%) were current and 332 (48%) previous
users. The proportion of women reporting an IDU history
declined from 36% (88/245) in 2000/01 to 29% (152/
530) in 2002/03, 24% (230/978) in 2004/05 and 14%
(219/1537) in 2006/07 (χ2
trend = 96.1, p < 0.001).
Timing of maternal HIV diagnosis
Most women received their first HIV diagnosis in preg-
nancy (Table 1). The proportion of women with a pre-
pregnancy HIV diagnosis increased slightly from 25%
(58/236) in 2000/01 to 31% (476/1536) in 2006/07,
whilst the proportions diagnosed in the third trimester
and intrapartum more than halved, decreasing in the
same years from 30% (71/236) to 14% (219/1536) and
from 10% (24/236) to 4% (65/1536) respectively. Among
women with unknown HIV status at the start of preg-
nancy, the proportion diagnosed in the first or second tri-
mester increased from 47% in 2000/01 (83/178) to 73%
(776/1060) in 2006/07 χ2 = 49.4, p < 0.001).
Factors associated with mothers having received a pre-
pregnancy HIV diagnosis were investigated (Table 2). An
IDU history, having an IDU sexual partner, moderate/
severe HIV symptoms and older age were significantly
associated with pre-pregnancy diagnosis; additionally,
women enrolling in 2006/07 were nearly twice as likely to
know their infection status before pregnancy as those
enrolling in 2000/01. Maternal HIV diagnosis intrapar-
tum was associated with IDU, with IDUs having a four-
fold increased risk of diagnosis at this late stage than other
women (Table 3). The reduced likelihood of intrapartum
diagnosis in the later years of the study lost statistical sig-
nificance in the adjusted model.
Use of antenatal and intrapartum antiretroviral 
prophylaxis
Overall, 93% of women received ARV drugs in pregnancy
or in labour (Table 1) and Figure 1 illustrates the time
trends in use of prophylaxis. The percentage of women
receiving no prophylaxis declined from 18% (36/205) in
2001 to 7% in 2007 (61/843) (χ2 = 11.0 p < 0.001). Intra-
partum HIV diagnosis, premature delivery and IDU were
associated with increased likelihood of women receiving
no prophylaxis, whilst increasing calendar period was
associated with a substantially decreased risk (Table 4).
Women receiving both ZDV and sdNVP were more likely
to have been diagnosed in the third trimester than women
receiving ZDV alone (23% [245/1088] vs 11% [125/
1126] χ2 = 51.8, p < 0.001), reflecting national policy;
duration of ZDV prophylaxis among women receiving
ZDV+sdNVP was half of that among women receiving
ZDV only (35 days vs 71 days). Median ZDV prophylaxis
duration increased from 24 to 72 days between 2000 and
2007. The proportion of women taking antenatal ZDV for
less than 31 days decreased from 62% in 2000/01 (63/
101) and 2002/03 (204/330) to 24% (153/643) in 2004/
05 and 7.5% (87/1160) in 2006/07 (χ2
trend = 493.0, p <
0.001). Antenatal HAART use increased from 1.6% (1/61)
in 2001 to 7% (60/844) in 2007. Of the 174 women onBMC Infectious Diseases 2009, 9:40 http://www.biomedcentral.com/1471-2334/9/40
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HAART, 16 (9%) had initiated this before pregnancy, with
a median duration of 82 weeks (range 44–160) before
pregnancy. The remaining women received HAART for a
median of 11 weeks (range 1–36) during pregnancy.
Infants
Overall, 34% (n = 1153) of infants were delivered by elec-
tive CS, 3% (n = 104) by emergency CS and 63% (n =
2099) vaginally. Among mother-child pairs from the
three centres enrolling since 2000 (n = 2809) elective CS
rates increased from 30% (62/205) in 2001 to 41% (210/
509) in 2007 (χ2
trend = 12.6, p < 0.001). Overall, there
were substantial centre differences, with an elective CS
rate of 60% (410/689) in Simferopol versus 10% (11/
115) in Kiev. Most neonates received ZDV prophylaxis
(Table 1), of whom, 85% (1708/2016) received one week
of ZDV syrup and 15% (n = 294) four weeks (no data on
duration for 12 children). Type of antenatal and/or intra-
partum prophylaxis was significantly associated with neo-
natal ZDV use, with neonatal prophylaxis taken by 44%
(108/246), 35% (228/654), 68% (1546/2281) and 83%
(145/174) of infants born to mothers who received no
ARV prophylaxis, sdNVP only, antenatal ZDV and HAART
respectively (χ2 = 296.4, p < 0.001).
A total of 35 (1%) infants were breastfed; there was no sig-
nificant trend over time, with 1.5% (4/267) breastfed in
2000/01, 0.7% (4/574) in 2002/03, 1.3% (13/978) in
Table 1: Characteristics of the HIV-infected pregnant women and their infants
N (%)
Median age (range) 25.6 years (14–44)
Parity at enrolment (n = 3324)
0 2026 (61)
1 966 (29)
≥2 332 (10)
History of pregnancy termination (n = 3325)
0 1948 (59)
1 715 (21)
≥2 662 (20)
Age at leaving full-time education
Median (IQR) 17 years (16–19)
Marital status (n = 3328)
Married 1372 (41)
Cohabiting 1324 (40)
Single, divorced, widowed 632 (19)
Mode of acquisition of HIV (n = 3356)
Injecting drug use 689 (21)
Injecting drug using partner 735 (22)
Other heterosexual contact 375 (11)
Other risk 9
No specific risk factor reported 1548 (47)
Timing of mother's first positive HIV test (n = 3356)
Before pregnancy 893 (27)
First/second trimester 1517 (45)
Third trimester 631 (19)
In pregnancy (date not specified) 81 (2)
Delivery 234 (7)
Maternal HIV clinical stage (n = 2956)
Asymptomatic/mild symptoms 2838 (96)
Moderate/severe symptoms 118 (4)
Gestational age (n = 3354)
<37 weeks 298 (9)
≥37 weeks 3056 (91)
Birth weight (n = 3354)
Median (range) 3100 g (850–5000 g)
Neonatal prophylaxis (n = 3356)
None 484 (14)
sdNVP only 773 (23)
ZDV 1907 (57)
sdNVP and ZDV 121 (4)
Type not recorded 71 (2)BMC Infectious Diseases 2009, 9:40 http://www.biomedcentral.com/1471-2334/9/40
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2004/05 and 0.9% (14/1537) in 2006/07 (p = 0.6). Three
of the breastfeeding mothers were diagnosed as HIV-
infected following intrapartum rapid testing, 14 through
antenatal testing and the remaining 18 (51%) diagnosed
pre-pregnancy. Median breastfeeding duration among the
10 mother-child pairs with information available was 2
weeks (range 1–23).
MTCT rates and risk factors
The overall MTCT rate was 11.4% (95%CI 9.9–13.0), with
192 children infected and 1498 uninfected; 1666 had
indeterminate status, of whom 1132 (68%) were aged
<18 months at the time of analysis. MTCT rates decreased
from 15.2% in 2001 (26/171, 95%CI 10.2–21.4) to 7.0%
in 2006 (6/86, 95%CI 2.6–14.6; limited to children aged
Table 2: Factors associated with diagnosis of HIV infection prior to pregnancy
N N (%) diagnosed pre-pregnancy Odds ratio (95% CI) Adjusted odds ratio (95% CI), p 
value
Mode of acquisition
Non IDU, no IDU sex partner 1573 338 (21) 1.00 1.00
Non IDU, IDU sex partner 696 195 (28) 1.42 (1.16–1.75) 1.46 (1.19–1.80) p < 0.001
IDU 601 263 (44) 2.85 (2.33–3.48) 2.94 (2.38–3.63) p < 0.001
Maternal age
<25 years 1303 298 (23) 0.65 (0.52–0.80) 0.79 (0.63–0.99) p = 0.04
25–30 years 939 300 (32) 1.02 (0.82–1.27) 1.12 (0.90–1.41) p = 0.31
≥30 years 629 198 (31) 1.00 1.00
Maternal moderate/severe HIV 
symptoms
No 2753 733 (27) 1.00 1.00
Yes 118 63 (53) 3.16 (2.18–4.58) 2.32 (1.57–3.42) p < 0.001
Time period of delivery
2000–2001 187 45 (24) 1.00 1.00
2002–2003 431 99 (23) 0.94 (0.63–1.41) 1.06 (0.70–1.60) p = 0.8
2004–2005 977 243 (25) 1.05 (0.73–1.51) 1.19 (0.81–1.74) p = 0.37
2006–2007 1276 409 (32) 1.49 (1.04–2.12) 1.87 (1.29–2.72) p < 0.001
95%CI – 95% confidence interval
Table 3: Factors associated with intrapartum diagnosis of HIV infection
N N (%) diagnosed intra-partum Odds ratio (95% CI) Adjusted odds ratio (95% CI), p value
Mode of acquisition
Non IDU, no IDU sex partner 1433 97 (7) 1.00 1.00
Non IDU, IDU sex partner 523 26 (5) 0.72 (0.46–1.12) 0.73 (0.47–1.14) p = 0.17
IDU 380 99 (26) 4.85 (3.57–6.60) 3.62 (2.61–5.03) p < 0.001
Maternal age
<25 years 1117 75 (7) 1.00 1.00
25–30 years 727 73 (10) 1.55 (1.11–2.17) 1.30 (0.92–1.85) p = 0.17
≥30 years 492 74 (15) 2.46 (1.75–3.46) 1.90 (1.32–2.72) p < 0.001
Marital status
Single, divorced, widowed 425 69 (16) 1.00 1.00
Married or cohabiting 1911 153 (8) 0.45 (0.33–0.61) 0.55 (0.39–0.76) p < 0.001
Time period of delivery
2000–2001 169 21 (12) 1.00 1.00
2002–2003 373 49 (13) 1.07 (0.62–1.84) 1.27 (0.72–2.26) p = 0.40
2004–2005 734 87 (12) 0.95 (0.57–1.58) 1.16 (0.67–1.98) p = 0.60
2006–2007 1060 65 (6) 0.46 (0.27–0.78) 0.66 (0.38–1.15) p = 0.14
95%CI – 95% confidence intervalBMC Infectious Diseases 2009, 9:40 http://www.biomedcentral.com/1471-2334/9/40
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≥18 months old at last follow-up visit). Unadjusted MTCT
rates by mode of delivery were 14.0% (141/1010, 95%CI
11.9–16.3) for vaginal deliveries, 19.3% (11/57, 95%CI
10.0–31.9) for emergency CS and 6.5% (40/623, 95%CI
4.7–8.8) for elective CS deliveries. Among women receiv-
ing no ARV prophylaxis, the unadjusted MTCT rate was
26.7% (32/120, 95%CI 19.0–35.5), decreasing to 15.7%
(62/395, 95%CI 12.3–19.7) with sdNVP only, 7.0% (20/
286, 95%CI 4.3–10.6) with ZDV, 9.2% (75/813, 95%CI
7.3–11.4) with ZDV and sdNVP and 3.9% (3/76, 95%CI
0.8–11.1) with HAART. Overall, IDUs had a significantly
higher unadjusted MTCT rate compared with women with
no IDU history (16.4% [67/409] vs 9.9% [121/1226] χ2 =
12.2, p < 0.001), but within the IDU group MTCT rates
were similar between women with current and prior use
(16.5% [33/200] vs 16.3% [34/209] respectively, p =
0.95). Sixteen of the 35 breastfed infants had known
infection status at last follow up, of whom 6 (37.5%) were
infected (95%CI 15.2–64.6%).
Maternal HIV clinical disease stage (classified as asympto-
matic/mild [WHO clinical stages 1 and 2] vs moderate/
severe [stages 3 and 4]) was not significantly associated
with MTCT risk (p = 0.96). MTCT risk more than doubled
with premature delivery, increased 1.8-fold with maternal
IDU history and five-fold with any breastfeeding in uni-
variable analysis, while use of ARV prophylaxis and elec-
tive CS significantly decreased transmission risk (Table 5).
In adjusted analysis, risk of transmission was reduced by
43% for women delivering by elective CS versus vaginal
delivery and use of sdNVP halved transmission risk, with
the reduction increasing to 86% for women on antenatal
HAART (Table 5). Women receiving ZDV only were 72%
less likely to transmit than those untreated (Table 5), and
50% less likely than women on sdNVP only (AOR 0.50;
95%CI 0.29–0.88, p = 0.02).
Discussion
In this cohort of HIV-infected pregnant women and their
infants, we have explored the effectiveness of the Ukraine
PMTCT programme in operational settings. We have doc-
umented earlier diagnosis of HIV-infected pregnant
women, increasing coverage with ARV prophylaxis and
decreasing MTCT rates, against a background of increasing
annual enrolments. The absolute numbers of IDU women
enrolling in the study actually increased in 2007 com-
pared to 2006 (data not shown), but we report a declining
proportion of women with IDU history over time, reflect-
ing trends towards increasing heterosexual transmission
in the Ukraine [3,15]. MTCT rates more than halved
between 2001 and 2006, with around one in fourteen
women transmitting infection to their infants in 2006.
Table 4: Factors associated with non-receipt of antenatal or intrapartum antiretroviral prophylaxis
N N (%) with non-receipt Odds ratio (95% CI) Adjusted odds ratio (95% CI) p value
Time of maternal HIV diagnosis
Pre-pregnancy 886 93 (11) 1.00 1.00
1st/2nd trimester 1500 18 (1) 0.10 (0.06–0.17) 0.12 (0.07–0.20) p < 0.001
3rd trimester 617 50 (8) 0.75 (0.52–1.08) 0.79 (0.54–1.15) p = 0.21
Intrapartum 221 68 (31) 3.79 (2.65–5.42) 3.43 (2.34–5.01) p < 0.001
Maternal age
<25 years 709 69 (10) 1.00 1.00
25–30 years 1453 84 (6) 0.57 (0.41–0.79) 0.87 (0.60–1.25) p = 0.45
≥30 years 1062 76 (7) 0.72 (0.51–1.01) 0.86 (0.59–1.24) p = 0.41
Mode of acquisition
Non IDU, no IDU sex partner 1829 106 (6) 1.00 1.00
Non IDU, IDU sex partner 728 27 (4) 0.63 (0.41–0.96) 0.60 (0.38–0.93) p < 0.001
IDU 667 96 (14) 2.73 (2.04–3.66) 1.44 (1.03–2.01) p < 0.001
Gestational age at delivery
≥37 2937 176 (6) 1.00 1.00
<37 287 53 (18) 3.55 (2.54–4.97) 2.21 (1.53–3.18) p < 0.001
Time of delivery
2000–2001 224 38 (17) 1.00 1.00
2002–2003 488 26 (5) 0.28 (0.16–0.47) 0.23 (0.13–0.41) p < 0.001
2004–2005 978 68 (7) 0.37 (0.24–0.56) 0.37 (0.23–0.60) p < 0.001
2006–2007 1534 97 (6) 0.33 (0.22–0.50) 0.43 (0.28–0.68) p < 0.001
95%CI – 95% confidence intervalBMC Infectious Diseases 2009, 9:40 http://www.biomedcentral.com/1471-2334/9/40
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Prompt identification of HIV-infected pregnant women is
essential for a successful PMTCT programme [12]. Around
one in four women here were aware of their HIV diagnosis
before conception, and nearly three-quarters had been
diagnosed by the start of their third trimester. Women
with IDU histories or IDU sexual partners and those with
HIV symptoms were more likely to have a pre-pregnancy
HIV diagnosis than other women which probably indi-
cates their increased likelihood of accessing voluntary
counseling and testing (VCT) outside pregnancy com-
pared with other women. The increased likelihood of pre-
pregnancy diagnosis in 2006/07 versus 2000/01 suggests
improvements in VCT coverage over time; a national pro-
tocol for VCT was not approved by the Ministry of Health
until December 2005, which is consistent with this time
trend. Access to harm reduction programmes for IDUs
increased nationwide within the framework of a Global
Fund supported programme, particularly during 2005–
2007, which is also likely to have contributed to increas-
ing coverage of VCT for IDUs, including female IDUS.
Among women becoming pregnant with unknown HIV
status, IDUs were more than 3.5 times more likely to be
diagnosed through intrapartum rapid testing than women
with a non-IDU-related mode of acquisition, indicating
reduced access to antenatal care and thus the application
of less effective PMTCT interventions. It is well recognised
that this marginalised group of women frequently experi-
ence problems accessing health and social services
[22,23]. In a study in St Petersburg, Russian Federation
among women presenting in labour with unknown HIV
status, largely without antenatal care, two-thirds were
IDUs [24]; HIV seroprevalence was 6.5% among women
without antenatal testing, substantially higher than the 1–
2% among women accessing antenatal care [25,26].
Our results indicate the greater effectiveness of antenatal
ZDV compared with sdNVP in PMTCT, consistent with
previous findings [12]. As the few women receiving ante-
natal HAART had clinical and/or immunological indica-
tions for HIV treatment, which are associated with
increased MTCT risk [9], one might potentially expect a
greater reduction in transmission risk than the 84% seen
here associated with HAART use if HAART were imple-
mented as prophylaxis for all women [13,15], which is
planned for Ukraine's next PMTCT programme, from
2009. Around 18% of women delivering in 2007 received
sdNVP alone or with ZDV. Although current WHO guide-
lines [12] recommend that where possible a 3TC and ZDV
"tail" should be provided postnatally for mothers receiv-
ing sdNVP, to reduce the likelihood of NVP resistance
developing [16], this was not included within the Ukraine
PMTCT programme. It remains unclear to what extent
NVP resistance could compromise success of subsequent
treatment of mother and child with NNRTI-containing
regimens [27-30].
Elective CS was an effective PMTCT intervention in this
setting, associated with a near-halving of risk, consistent
with earlier results in Western Europe [14,31-33]. How-
ever, we documented considerable variation in the appli-
cation of this PMTCT intervention across our study sites.
Ukraine is a setting where formula feeding is acceptable,
feasible, affordable, sustainable and safe and this is rec-
ommended for all HIV-positive women within the
national policy. Although free breast milk substitutes are
theoretically available, there are historic reports of limited
access for some women [18,34]. Only around 1% of
infants were breastfed, mostly for short durations. Breast-
feeding was associated with a three-fold increased MTCT
risk, although we were unable to determine the timing of
transmission among HIV-positive breastfed infants. These
findings are a pertinent reminder that appropriate feeding
counselling and support for HIV-infected women [35] are
needed even in settings where avoidance of breastfeeding
is not generally perceived as problematic.
The halving of the MTCT rate since 2001 documented
here marks the success of the national PMTCT pro-
gramme, although key challenges remain which must be
addressed if the country is to achieve the Dublin Declara-
tion target of "virtual elimination" of HIV transmission to
infants by 2010 [36]. Women least likely to receive ARV
prophylaxis included IDUs and those diagnosed intrapar-
tum, which mirrors findings from elsewhere in Europe
[37-39]. Efforts are needed to address barriers that these
women may face in accessing services, particularly as
many may have concurrent infections, including hepatitis
C [40] and sexually transmitted infections [41]. Linkages
between harm reduction, oral substitution therapy and
PMTCT services need to be established, with development
of services targeted at hard-to-reach IDU pregnant
Trends in use of antenatal and intrapartum antiretroviral  prophylaxis/treatment Figure 1
Trends in use of antenatal and intrapartum antiret-
roviral prophylaxis/treatment.
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women. It will also be important to improve quality of
PMTCT interventions, including better access to CD4
count monitoring and HAART and improved coverage of
early infant diagnosis. Primary prevention of HIV acquisi-
tion in women is the most effective approach for prevent-
ing infections in infants [11,23], but services in Ukraine
remain under-developed, both those directed to at risk
populations, such as IDUs, and for the general popula-
tion. Nearly half of the women here reported no specific
risk factors for HIV and most likely acquired infection het-
erosexually. As Ukraine has an HIV prevalence exceeding
1.5%, increasing heterosexual transmission and a young
HIV-positive population (three-quarters aged 30 or less)
[8,42], it is essential that concerted effort is directed
towards primary prevention, as recommended by the
recent UNAIDS-coordinated External Evaluation of the
National AIDS Response [38].
Our study was limited by the observational nature of the
data and although we adjusted for confounding factors in
our multivariable analyses, there is potential for unmeas-
ured confounding. Other limitations included the paucity
of maternal CD4 counts and lack of HIV RNA measure-
ments, which were not widely available within routine
clinical practice. In a setting with limited access to early
diagnosis for HIV-exposed infants, scope for loss to fol-
low-up before infection status can be determined is con-
siderable. Here, 15% of infants had indeterminate
infection status despite being aged >18 months; applying
the relevant transmission risks for the five strata of ARV
prophylaxis applicable to these 535 children, we estimate
that an estimated 65 (12.1%) would be infected. Adding
this figure to the 1690 children with known infection sta-
tus gives an overall MTCT estimate of 11.6% (c.f. 11.4%
reported). Regarding the generalizability of our results, of
the estimated 2731 HIV-infected women who delivered
nationally in 2007 [38], nearly a third were enrolled in the
ECS, suggesting that our cohort is representative of the
HIV-infected pregnant population in Ukraine. Of note, as
the ECS only includes women who deliver, characteristics
may differ from women terminating their pregnancies.
Conclusion
Data from our study not only provide valuable informa-
tion for the evaluation and strengthening of Ukraine's
PMTCT programme, but also for the ongoing develop-
ment of strategies for prevention of HIV infection in
infants elsewhere in Eastern Europe and Central Asia. The
experience in Ukraine highlights that it is possible for a
lower income country to make a substantial impact on
MTCT (in this case, having of the MTCT rate in only five
years) and underscores the appropriateness of the public
health approach to prevention of HIV infections in infants
recommended by WHO [10] and adopted in Ukraine with
obvious success. Future research should focus on hard-to-
reach populations such as IDU, in addition to the urgent
issues of primary prevention and prevention of unin-
tended pregnancies among HIV-positive women. In par-
ticular, scaling-up prevention of heterosexual
transmission of HIV from and among IDUs will contrib-
ute to PMTCT in Ukraine.
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Table 5: Risk factors associated with mother-to-child transmission
N Odds ratio (95%CI) Adjusted odds ratio (95%CI), p value
Premature delivery
No 1491 1.00 1.00
Yes 144 2.22 (1.44–3.43) p < 0.001 1.43 (0.90–2.28) p = 0.13
Mode of delivery
Vaginal 964 1.00 1.00
Emergency CS 57 1.44 (0.73–2.86) p = 0.29 1.58 (0.78–3.19) p = 0.20
Elective CS 614 0.42 (0.29–0.61) p < 0.001 0.57 (0.38–0.86) p = 0.007
Antenatal/intrapartum ARVs
None 110 1.00 1.00
SdNVP 370 0.49 (0.30–0.81) p = 0.006 0.55 (0.33–0.92) p = 0.02
ZDV 280 0.20 (0.11–0.36)  p< 0.001 0.28 (0.14–0.53) p < 0.001
ZDV with sdNVP 799 0.26 (0.16–0.42) p < 0.001 0.41 (0.24–0.69) p < 0.001
HAART 76 0.11 (0.03–0.36) p < 0.001 0.16 (0.05–0.54) p = 0.004
IDU history
No 1266 1.00 1.00
Yes 409 1.79 (1.30–2.47) p < 0.001 1.31 (0.92–1.86) p = 0.13
Breastfeeding
None 1620 1.00 1.00
Any 15 5.27 (1.85–15.0) p = 0.002 3.07 (1.02–9.24) p = 0.046
95%CI – 95% confidence intervalBMC Infectious Diseases 2009, 9:40 http://www.biomedcentral.com/1471-2334/9/40
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